Bristol-Myers Squibb Co.

History

Year	Detail
1887	BRISTOL-MYERS SQUIBB CO. was founded as CLINTON PHARMACEUTICALS.
1892	Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons.
1895	First breakthrough a product called Sal Hepatica salts, marketed as a tonic and laxative.
1899	Bristol and Myers rename their business the Bristol, Myers Company, which outgrows its home in Clinton, New York. The company relocates — first to Syracuse and then, in 1899, to Brooklyn to better serve customers in New England and Pennsylvania.
1901	Bristol-Myers introduces Ipana toothpaste, featuring a disinfectant to prevent tooth decay and gum disease.
1902	E.R. Squibb & Sons establishes its first quality-control laboratory.
1905	E.R. Squibb & Sons purchases an ether manufacturing plant in what was then the wilds of New Brunswick, New Jersey.
1914	Squibb Biological Laboratories division produces antitoxins, serums and vaccines.
1917	E.R. Squibb & Sons pioneers the standardization of digitalis, derived from the foxglove plant as an early treatment for heart conditions.
1919	The company expands westward by opening a distribution center in Chicago, and also organizes an export department in Brooklyn.
1938	Established Squibb Institute for Medical Research in New Brunswick, New Jersey.
1943	Bristol-Myers acquires Cheplin Laboratories in Syracuse, New York, enabling it to mass produce penicillin during World War II. This marks the company’s entry into ethical drug development.
1944	Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.
1948	Bristol Laboratories introduces Flo-Cillin 96, a long-lasting injectable penicillin and also introduced Bufferin, a new pain reliever.
1956	Bristol-Myers enters the cancer drug development field, building on collaborations around promising antibiotics with the Microbial Chemistry Research Foundation of Japan.
1959	Bristol-Myers acquires the hair-coloring company Clairol, which was founded in 1931 by Joan and Lawrence M. Gelb. Their son, Richard L. Gelb.
1966	Bristol-Myers Products research and development laboratories in Hillside, New Jersey.
1967	Bristol-Myers acquires Mead Johnson.
1971	Squibb establishes worldwide headquarters in Princeton, New Jersey.
1974	Bristol Laboratories introduces cancer chemotherapy agent Blenoxane.
1983	The FDA approves Bristol Laboratories VePesid.
1989	Bristol-Myers merges with Squibb, creating a global leader in the health care industry.
1991	FDA approves TAXOL.
1997	Bristol-Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.
1998	President Bill Clinton awards the National Medal of Technology — America’s highest honor for technological innovation — to Bristol-Myers Squibb.
1999	The Bristol Myers Squibb Foundation announces SECURE THE FUTURE.
2001	The Bristol-Myers Squibb Children’s Hospital opens as part of Robert Wood Johnson University Hospital in New Brunswick, New Jersey.
2001	Acquired DuPont pharmaceuticals.
2008	Celgene and Accerleron Pharma announce research collaboration to develop therapies for cancer and other rare diseases.
2009	Bristol Myers Squibb acquires Medarex, Inc.
2010	Celgene and Agios Pharmaceutical, Inc. announce global strategic collaboration focused on targeting cancer metabolism.
2018	Celgene gains INREBIC (fedratinib) from IMPACT BioMedicines purchase.
2018	The acquisition contributes to Celgene’s stature as a premier cellular immunotherapy.
2019	European Commission approves combination regimen for REVLIMID (lenalidomide) and Imnovid (pomalidomide).
2019	Bristol-Myers Squibb acquired Celgene.
2020	Bristol Myers Squibb acquires MyoKardia.
2021	Bristol Myers Squibb and Eisai announce global strategic collaboration for Eisai’s antibody drug conjugate.
2022	Bristol Myers Squibb acquires Turning Point Therapeutics.